DE60239318D1 - Antibakterielle impfstoffzusammensetzungen - Google Patents

Antibakterielle impfstoffzusammensetzungen

Info

Publication number
DE60239318D1
DE60239318D1 DE60239318T DE60239318T DE60239318D1 DE 60239318 D1 DE60239318 D1 DE 60239318D1 DE 60239318 T DE60239318 T DE 60239318T DE 60239318 T DE60239318 T DE 60239318T DE 60239318 D1 DE60239318 D1 DE 60239318D1
Authority
DE
Germany
Prior art keywords
vaccine compositions
antibacterial vaccine
antibacterial
compositions
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239318T
Other languages
English (en)
Inventor
David E Lowery
Troy E Fuller
Michael J Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of DE60239318D1 publication Critical patent/DE60239318D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
DE60239318T 2001-03-15 2002-01-17 Antibakterielle impfstoffzusammensetzungen Expired - Lifetime DE60239318D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions
PCT/US2002/001971 WO2002075507A2 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
DE60239318D1 true DE60239318D1 (de) 2011-04-14

Family

ID=25201919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239318T Expired - Lifetime DE60239318D1 (de) 2001-03-15 2002-01-17 Antibakterielle impfstoffzusammensetzungen

Country Status (18)

Country Link
US (2) US6790950B2 (de)
EP (1) EP1368456B1 (de)
JP (2) JP2005502315A (de)
AR (2) AR035745A1 (de)
AT (1) ATE500316T1 (de)
AU (1) AU2002240033B2 (de)
CA (2) CA2438315C (de)
CY (1) CY1112014T1 (de)
DE (1) DE60239318D1 (de)
DK (1) DK1368456T3 (de)
ES (1) ES2362041T3 (de)
MX (1) MXPA03008296A (de)
NZ (1) NZ528208A (de)
PE (1) PE20021008A1 (de)
PT (1) PT1368456E (de)
SI (1) SI1368456T1 (de)
TW (4) TWI328035B (de)
WO (1) WO2002075507A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
EP1171577A2 (de) * 1999-04-09 2002-01-16 PHARMACIA & UPJOHN COMPANY Antibakterielle vakzinzusammensetzungen
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP2010505831A (ja) * 2006-10-05 2010-02-25 ニューヨーク ブラッド センター， インコーポレイテッド 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
EP2283033A1 (de) 2008-05-06 2011-02-16 New York Blood Center Antivirale zellenpenetrierende peptide
CA2729818A1 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
ES2824402T3 (es) 2013-11-01 2021-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
CA2099841C (en) 1991-03-05 2003-02-25 Ian G. Charles Expression of recombinant proteins in attenuated bacteria
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
JPH08503136A (ja) 1992-11-06 1996-04-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995020652A1 (de) 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
NZ296581A (en) 1994-12-09 2000-02-28 Imp College Innovations Ltd A method of identifying genes identified in a microorganisms ability to adapt to changes in its environment
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU723380B2 (en) * 1996-09-06 2000-08-24 Peter Ruhdal Jensen A method of improving the production of biomass or a desired product from a cell
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
EP1171577A2 (de) 1999-04-09 2002-01-16 PHARMACIA & UPJOHN COMPANY Antibakterielle vakzinzusammensetzungen
AU4204800A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
EP1278768B1 (de) * 2000-04-27 2006-11-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Methode zur identifizierung von helicobacter antigenen

Also Published As

Publication number Publication date
SI1368456T1 (sl) 2011-06-30
ES2362041T3 (es) 2011-06-27
JP2011097938A (ja) 2011-05-19
US20050003512A1 (en) 2005-01-06
MXPA03008296A (es) 2007-05-28
TW201040261A (en) 2010-11-16
US20040110268A1 (en) 2004-06-10
EP1368456B1 (de) 2011-03-02
US7476391B2 (en) 2009-01-13
TWI334884B (en) 2010-12-21
CA2852293A1 (en) 2002-09-26
AR071888A2 (es) 2010-07-21
WO2002075507A2 (en) 2002-09-26
TW200916577A (en) 2009-04-16
CY1112014T1 (el) 2015-11-04
WO2002075507A3 (en) 2003-09-12
PE20021008A1 (es) 2002-11-13
NZ528208A (en) 2008-04-30
CA2438315C (en) 2014-09-02
TWI328035B (en) 2010-08-01
WO2002075507B1 (en) 2003-12-11
TWI335934B (en) 2011-01-11
PT1368456E (pt) 2011-06-01
ATE500316T1 (de) 2011-03-15
JP2005502315A (ja) 2005-01-27
TW201040262A (en) 2010-11-16
TWI335935B (en) 2011-01-11
CA2438315A1 (en) 2002-09-26
DK1368456T3 (da) 2011-05-23
AU2002240033B2 (en) 2007-11-08
EP1368456A2 (de) 2003-12-10
AR035745A1 (es) 2004-07-07
US6790950B2 (en) 2004-09-14

Similar Documents

Publication Publication Date Title
ATE553775T1 (de) Impstoffzusammesetzung
ATE420159T1 (de) Grippe-impfstoffzusammensetzung
FI20010780A0 (fi) Parannetut koostumukset
NO20026175L (no) Vaksinesammensetning
DE60232172D1 (de) Nanocomposit-widerstands zusammensetzungen
IS6915A (is) Lyfjablanda
ATE246449T1 (de) Antimikrobielle zusammensetzungen
FI20011478A (fi) Farmaseuttinen koostumus
ATE289796T1 (de) Orale zusammensetzung
DK1427444T3 (da) West-nil-vaccine
IS7297A (is) Streptococcis Pneumoniae bóluefni
BR0210619A (pt) composição
NO20033882L (no) Vaksine
IS7051A (is) Lyfjasamsetningar
IS7081A (is) Lyfjablanda
ATE500316T1 (de) Antibakterielle impfstoffzusammensetzungen
FI20022128A0 (fi) Farmaseuttinen koostumus
ATE450652T1 (de) Wässrige zusammensetzung
PT1238587E (pt) Composicoes de biopesticidas
DE60135877D1 (de) Antibakterielle zusammensetzung
ITTO20020747A0 (it) Composizione
ITMI20010884A0 (it) Composizioni detergenti
ATE549920T1 (de) Insektizide zusammensetzung
ITTO20020745A0 (it) Composizione
NO20030946L (no) Medisinske sammensetninger